Stock·LSE·£
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in the United States, dedicated to discovering and advancing novel therapeutic agents for immune-inflammatory diseases. The company operates through two distinct divisions: Therapeutics and Contract Research. The Therapeutics segment focuses on identifying and developing cutting-edge treatments to address significant unmet medical needs within the realm of immunological and inflammatory conditions. Complementing this, the Contract Research segment offers specialized laboratory services. Aclaris boasts a robust development pipeline, featuring several key drug candidates. These include Zunsemetinib, an MK2 inhibitor, currently being developed to treat moderate to severe rheumatoid and psoriatic arthritis, as well as hidradenitis suppurativa. Another significant asset is ATI-1777, a soft JAK 1/3 inhibitor, targeting moderate to severe atopic dermatitis. Furthermore, the company is progressing with ATI-2138, an ITK/TXK/JAK3 inhibitor for T cell-mediated autoimmune diseases; a Gut-Biased Program aimed at inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, intended for pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics maintains its principal office in Wayne, Pennsylvania.
See 0H8T.L price live on your physical desk display. Set alerts with iOS & Android apps.
